13-cis-Retinoic acid induces cellular differentiation and durable remission in refractory cutaneous Ki-1 lymphoma

J. M. Chow, A. L. Cheng, I. J. Su, C. H. Wang

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

A 35-year-old man with refractory cutaneous Ki-1 lymphoma was salvaged successfully with oral 13-cis-retinoic acid (1 mg/kg/day). He had a complete remission lasting for 20 months before a single nodule recurred on his skin. Excisional biopsy of the recurrent tumor revealed a distinct morphologic change, suggesting cellular differentiation toward a more benign phenotype. No significant side effects were noted except mild xerostomia, bone pain, and hyperlipidemia. The authors believe that 13-cis-retinoic acid should be considered in the treatment of cutaneous Ki-1 lymphoma.

Original languageEnglish
Pages (from-to)2490-2494
Number of pages5
JournalCancer
Volume67
Issue number10
Publication statusPublished - 1991
Externally publishedYes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of '13-cis-Retinoic acid induces cellular differentiation and durable remission in refractory cutaneous Ki-1 lymphoma'. Together they form a unique fingerprint.

  • Cite this